Skip to main content
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. — Investor Relations & Filings

Ticker · ELVN ISIN · US29337E1029 US Manufacturing
Filings indexed 719 across all filing types
Latest filing 2026-03-27 Director's Dealing
Country US United States of America
Listing US ELVN

About Enliven Therapeutics, Inc.

https://www.enliventherapeutics.com/

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company focuses on the discovery and development of small molecule kinase inhibitors for patients with cancer. Its approach is to create potentially best-in-class or first-in-class therapeutics that address unmet medical needs by enhancing efficacy through improved selectivity, combating treatment resistance, addressing brain metastases, and improving safety and patient convenience.

Recent filings

Filing Released Lang Actions
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
Director's Dealing
2026-03-27 English
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
Regulatory Filings
2026-03-25 English
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
Director's Dealing
2026-03-19 English
10-K - ENLIVEN THERAPEUTICS, INC. (0001672619) (Filer)
Annual Report FY 2025
2026-03-03 English
8-K - ENLIVEN THERAPEUTICS, INC. (0001672619) (Filer)
Regulatory Filings
2026-03-03 English
4 - ENLIVEN THERAPEUTICS, INC. (0001672619) (Filer)
Director's Dealing
2026-02-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.